Skip to main content
TipRanks
Go Ultimate75% OFF

Allogene Therapeutics (ALLO) Q3 2026 Earnings Report

1,853 Followers

ALLO Q3 2026 EPS Results

Actual EPS
-$0.15
Consensus EPS
-$0.15
Beat/Miss
Missed by -$0.00
One Year Ago EPS
-$0.19

ALLO Q3 2026 Revenue Results

Actual Revenue
$0
Expected Revenue
$2,000
Beat/Miss
Missed by -$2,000
YoY Revenue Growth
―

Earnings Announcement Details

Quarter
Q3 2026
Date
11/05/2026
Time
After Close
Conference Call
Thursday, November 5, 2026
ALLO Upcoming Earnings

Allogene Therapeutics's next earnings date is estimated for March 18, 2027, based on past reporting schedules.

Q3 2026 Earnings Call Audio

ALLO Q3 2026 Earnings Call
0:00 / 0:00

Q3 2026 Earnings Slide Deck

No slide deck is available for this earnings event.

Q3 2026 Earnings Call Summary

Q3 2026
Earnings Call Date:Nov 05, 2026|% Change Since:-31.74%|
Earnings Call Sentiment|Positive

The call was strongly optimistic, driven by encouraging interim findings and safety observations for cema-cel and ALLO-329, increasing enrollment and MRD-screening activity, rapid Asia-Pacific participation, and continued progress toward 2027 milestones. The company also acknowledged early ALPHA3 execution challenges, limited statistical alpha at the interim look, two serious adverse events in ALLO-329 dose level 2, chemotherapy-related infectious-risk considerations, and uncertainty around competitive and future clinical data.

Company Guidance

Allogene continues to guide toward the next clinical update for ALPHA3 in mid-2027 and enrollment completion by the end of next year, with the company stating it is on track for completion of the study by the end of next year and that it does not see any reason to change that guidance; it expects to present expanded ALLO-329 data on November 9, including additional patients, longer follow-up, three dose levels, and three conditioning approaches.

  • ALPHA3 Interim Analysis Showed Encouraging Early FindingsThe interim futility analysis earlier in 2026 provided encouraging evidence of rapid MRD clearance, a favorable early safety profile, and feasibility of administering cema-cel in community practices, including centers with no prior CAR-T experience.
  • ALPHA3 Enrollment Momentum and Timeline Remain StrongEnrollment momentum continues, supported by increased MRD screening, strong investigator engagement, and brisk activity in the Asia-Pacific region. Per-site productivity has increased, Korea and Australia began screening and enrolling quickly after site activation, and the company continues to guide toward enrollment completion by the end of 2027, with a clinical update expected in mid-2027.
  • Growing MRD Screening Supports Trial RecruitmentThe company said MRD adoption has grown across oncology, particularly lymphoma, and that commercial sales of MRD tests within lymphoma have been spiking quarter over quarter. Broader MRD adoption, educational efforts, early cema-cel data, and the global expansion of ALPHA3 are contributing to better screening and enrollment cadence.
  • Cema-cel Shows Community and Outpatient PotentialManagement said confidence is very high that cema-cel is outpatient-friendly and community-ready. The trial continues to screen and treat patients in these settings, community-practice interest surged over the summer, additional practices are being onboarded, and the safety profile has remained very good with trained sites and required medications available to manage CRS or other post-infusion events.
  • Asia-Pacific Enrollment Is Rapid but Expected to Remain BalancedAustralia and Korea are screening and enrolling at an impressive pace because patients are concentrated in large treatment centers. Despite this activity, the company expects Asia-Pacific sites to remain a relative minority of overall ALPHA3 enrollment and said it is not concerned about an enrollment imbalance affecting FDA interpretability; U.S. sites also continue to show strong activity.
  • Strategic Focus on MRD-Positive LymphomaAllogene said its 2024 strategy shifted cema-cel away from a traditional late-line development pathway toward MRD-positive lymphoma, where earlier identification of relapse risk creates a potential opportunity for off-the-shelf CAR-T to change the timing and setting of treatment.
  • Planned Commercial-Access and Treatment-Delivery WorkThe company is evaluating the total cost of care, patient and caregiver burden, reimbursement, site readiness, and treatment-delivery economics for allogeneic CAR-T. At ASH, it plans to share a survey of 152 U.S. hematologists and oncologists on barriers to CAR-T adoption and host an investor event on how cema-cel could address those barriers.
  • ALLO-329 Has Had Favorable Early Safety FindingsTo date, the company has observed no high-grade toxicities or cases of IEC-HS with ALLO-329. Management also said it has not seen anything concerning so far across CRS, ICANS, or infections, while detailed monitoring and management guidance from prior ALLO-316 experience was incorporated into the RESOLUTION protocol.
  • ALLO-329 Data Expansion at ACROn November 9, Allogene plans to present an expanded clinical and translational dataset for ALLO-329 at ACR, including additional patients, longer follow-up, three dose levels, and three conditioning approaches. The analysis will examine CAR-T activity and clinical responses across different conditioning regimens.
  • DAGGER Technology Targets Reduced Chemotherapy ConditioningALLO-329 was designed with DAGGER technology to address allogeneic rejection and potentially reduce reliance on chemotherapy-based lymphodepletion. The company is evaluating cohorts with no lymphodepletion, Cytoxan alone, and Flu/Cy, with the goal of achieving activity while reducing chemotherapy burden, treatment risk, and treatment complexity.
  • Scleroderma Has Emerged as the Leading ALLO-329 Enrollment PathwayScleroderma, specifically diffuse cutaneous systemic sclerosis, has been the most active enrollment pathway in the RESOLUTION basket. Management said it has a strong group of patients for the upcoming efficacy update, while patients with lupus and myositis remain eligible and the trial design has not been changed.
  • ALLO-329 Has a Differentiated Product DesignManagement stated that ALLO-329 is the only product in the discussed field targeting both CD19 and CD70. The company believes CD70 has a broad role in inflammatory processes and that the dual-target design, together with the potential to reduce or eliminate chemotherapy-based lymphodepletion, differentiates the program.
  • Rapid ALLO-329 Trial EnrollmentAlthough the ALLO-329 trial opened less than a year ago, management said it has been impressed by how quickly the study has enrolled and described the program as being in a good place ahead of internal go/no-go decisions.
  • Frontline EPCORE Data Showed a Hazard Ratio Below 0.5Management noted that the reported frontline EPCORE hazard ratio was a little under 0.5, which was somewhat better than many expected. The company is continuing to monitor additional data, including the possibility of a later ASH presentation.
  • Platform Expansion and Research UpdatesAllogene plans to present its clinical experience with ALLO-316 in renal cell carcinoma and preclinical findings from its DLL3/CD70 dual CAR-T program at SITC. Management said lessons from its clinical programs are informing the next generation of the platform.
  • Finance Leadership Transition Has Planned ContinuityCFO Geoff Parker retires after the call, and the search for a new CFO is continuing. Management expressed full confidence in financial operations and controls under Annie Yoshiyama, who has 20 years of experience and has supported financial reporting and financing activities since joining Allogene in 2024.

ALLO Earnings History

ALLO earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Mar 18, 20272026 (Q4)-0.16--0.17――
Nov 05, 20262026 (Q3)-0.15-0.15-0.1921.05% (+0.04)
Aug 12, 20262026 (Q2)-0.17-0.13-0.2343.48% (+0.10)
May 13, 20262026 (Q1)-0.19-0.18-0.2835.71% (+0.10)
Mar 12, 20262025 (Q4)-0.23-0.17-0.2839.29% (+0.11)
Nov 06, 20252025 (Q3)-0.22-0.19-0.3240.63% (+0.13)
Aug 13, 20252025 (Q2)-0.27-0.23-0.3534.29% (+0.12)
May 13, 20252025 (Q1)-0.29-0.28-0.3826.32% (+0.10)
Mar 13, 20252024 (Q4)-0.33-0.28-0.5145.10% (+0.23)
Nov 07, 20242024 (Q3)-0.33-0.32-0.3713.51% (+0.05)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed